Background
==========

Breast cancer is the most common malignancy in women in Western countries, currently accounting for one third of all female cancers \[[@B1]\]. In Sardinia, breast cancer represents the principal death-causing malignancy, with an incidence similar to that observed in western countries \[[@B2]\]. Familial aggregation is thought to account for 5--10% of all breast cancer cases, and germline mutations in different genes involved in pathways critical to maintain the genomic integrity have accounted for less than 25% of the inherited breast cancer \[[@B3],[@B4]\]. Part of this familial clustering shows autosomal dominant inheritance with high penetrance due to mutations in the *BRCA1*(MIM 113705) and *BRCA2*(MIM 600185) breast cancer genes \[[@B5],[@B6]\]. Cumulative breast cancer risks by age 70 are estimated to be 65% for *BRCA1*and 45% for *BRCA2*mutation carriers. In addition, women with *BRCA*mutations are at significant risk to develop ovarian cancer and other malignancies \[[@B7]\].

Hundreds of mutations among breast/ovarian cancer families have been found in these two genes. According to the Breast Cancer Information Core (BIC) database \[[@B8],[@B9]\], about two thirds of germline variants identified in *BRCA1*and *BRCA2*are unique; the remaining ones are recurrent founder mutations which have been described in different ethnic groups and populations. Therefore, the mutation spectrum and prevalence of mutation carriers with breast or ovarian cancer depends on the population studied, and displays considerable variation based on ethnic and geographical diversity. In Italy, 4--27% of the identified mutations recurred among apparently unrelated families, while a regional founder effect has been demonstrated for few mutations \[[@B10]-[@B13]\]. In Sardinia, contribution of *BRCA1-2*mutations to breast cancer predisposition has been reported for populations from the Northern part of the island \[[@B14]\]. Sardinian population shows strong founder effects for several genetic diseases with some geographical differences within the island \[[@B15],[@B16]\]; indeed, some genetic heterogeneity has been described within the coastal or proximal-to-coast regions, which have suffered repeated invasions over many years, in comparison to the most internal and isolated part of the island \[[@B17]\]. On this regard, the assessment of both spectrum and prevalence of *BRCA1*and *BRCA2*mutations across the entire island as well as their predictive significance in this population is needed. Nevertheless, assessment of the likelihood of carrying deleterious mutations in *BRCA1*or *BRCA2*genes among patients who present high-risk cancer evaluation clinics will provide more accurate guidance to women and families about considering genetic testing \[[@B7]\].

Here we report on the prevalence and geographical distribution of *BRCA1-2*mutations within the entire Sardinian population. We also investigated the existence of any significant association between mutations in *BRCA1-2*genes and phenotypic characteristics of breast cancer patients that could drive specific treatment and influence the process of mutation testing.

Methods
=======

Family selection
----------------

A total of 1,085 unselected breast cancer patients was recruited from all clinics at the Universities and Hospitals across the Sardinia island. To avoid any bias, patients were consecutively collected from January 1998 to December 2003 and were enrolled regardless of age at diagnosis, family history status or disease features. Sardinian origin was ascertained in all cases through genealogical studies. Family history of cancer was evaluated through specific questionnaires during the follow-up visits at the participating institutions. Three-hundred-forty-eight (32%) presented a familial recurrence of invasive breast or ovarian carcinoma: 237 originated from North Sardinia, 66 from Middle and 45 from South. Part of the present cohort (112 familial cases with at least three affected members) had been already included in our previous studies \[[@B18],[@B19]\]. The remaining 737 (68%) breast cancer patients were sporadic cases.

Among patients with a family history of breast/ovarian cancer, 131/348 (37.6%) fulfilled the selection criterion for \"high risk\" families: presence of a breast cancer patient diagnosed before age 50 years and having at least one first- or second-degree relative diagnosed with breast cancer before 50 years of age or ovarian cancer at any age.

Of those, 73 originated from North Sardinia, 21 from the Middle and 37 from the South. The 81% of \"high risk\" families presented with breast cancer and the 12% with both breast and ovarian cancer. Male breast cancer was present in the 7% of the families (Table [1](#T1){ref-type="table"}). The remaining 217 families were categorized as \"no high risk\" families: presence of a breast cancer patient having at least one first- or second-degree relative who is diagnosed with breast cancer or ovarian cancer at any age.

###### 

*BRCA1*and *BRCA2*mutational analysis

  Characteristics               Cases     *BRCA*positive Families            
  ----------------------------- --------- ------------------------- -------- ----------
  TOTAL CASES\*                 348                                 35       10
                                                                             
  **\"High risk\"**             **131**                             **23**   **17.5**
   BC                           106       81                        17       16.0
   BC/OC                        16        12                        5        31.2
   MBC                          9         7                         1        11.1
   Age at diagnosis \<40 y      41        31                        12       29.2
                                                                             
  **\"No High risk\"**          **217**                             **12**   **5.5**
   BC                           204       94                        11       5.4
   BC/OC                        8         4                         1        12.5
   MBC                          5         2                         0        0.0
                                                                             
  **2 BC/OC in the family**     **114**                             **4**    **3.5**
  ≥ **3 BC/OC in the family**   **145**                             **17**   **11.7**

**High risk**: presence of a breast cancer patient diagnosed before age 50 years and having at least one first- or second-degree relative who is diagnosed with breast cancer before 50 years of age or ovarian cancer at any age). **No high risk**: presence of a breast cancer patient having at least one first- or second-degree relative who is diagnosed with breast cancer or ovarian cancer at any age. BC, breast cancer; OC, ovarian cancer; MBC, male breast cancer.

\* including 112 families already reported in our previous studies

According to number of breast/ovarian cancer in the families, we had 75 families with 3 or more affected members and 47 families with two affected members among the \"high risk\" cases; 67 families had 3 or more affected members and 70 families had two affected members among the \"no high risk\" cases. Information on total number of affected family members were uncertain or not available for 9 and 80 patients in the \"high risk\" and \"no high risk\" groups, respectively.

Clinical and pathological characteristics of the breast cancer probands including age at diagnosis, mono- or bilateral tumour location, stage of disease, tumour-node-metastasis system status, tumour grading, estrogen/progesterone receptor status, were confirmed by medical records and pathology reports.

Patients were informed about the aims of the study; blood samples for genetic testing were drawn after obtaining their written consent. The study was reviewed and approved by the ethical review boards of the participating Institutions accounting for samples\' collection (University of Sassari; Azienda Sanitaria Locale of Sassari, Nuoro and Cagliari).

Mutation detection
------------------

Mutation analysis of coding sequences and intron-exon boundaries of the *BRCA1*and *BRCA2*genes was carried out in the series of 348 probands from families with hereditary breast cancer. Genomic DNA was obtained from isolated white blood cells by salting out procedure \[[@B20]\]. Mutation detection for all coding regions and splice boundaries of *BRCA1*and *BRCA2*genes was performed by single strand conformation polymorphism (SSCP) for a small fraction of cases (27 family probands); all remaining cases underwent mutational screening by denaturing high performance liquid chromatography (DHPLC), using the WAVE Nucleic Acid Fragment Analysis System (Transgenomic, Omaha, NE), followed by automated sequencing as previously reported \[[@B18],[@B19]\]. To confirm that each germline variant detected by sequencing was a real mutation and not a polymorphism, 103 unrelated normal individuals (corresponding to 206 chromosomes), originating from the same geographical area and with no family history for breast cancer, were used as controls and screened for each gene variant identified. For sequence homology searches, National Center for Biotechnology Information Blast database <http://www.ncbi.nlm.nih.gov/BLAST/> has been used \[[@B21]\]. All identified variants were verified for their existence and nomenclature into the BIC database <http://research.nhgri.nih.gov/bic/> and the Human Gene Mutation Database <http://www.hgmd.cf.ac.uk/ac/>\[[@B22]-[@B24]\].

Statistical Analysis
--------------------

The Pearson\'s Chi-Squared test was used for assessing the existence of any correlation between occurrence of deleterious germline mutations in *BRCA1*, *BRCA2*, or either gene and probands\' characteristics. The following variables and categories were defined and included in our analyses: presence of ovarian or male breast cancer in family, synchronous or asynchronous bilateral breast carcinoma, age at diagnosis, histological tumor grade as standardized by Elston and Ellis \[[@B25]\], disease stage (pathological primary tumor size, pathological nodal status, presence of metastases) according to TNM classification which describes the anatomical extended of the disease by Sobin et al \[[@B26]\], estrogen and progesterone receptor status. The exact coefficient for sample proportion analysis was calculated to determine all of the significant parameters (below the 0.05 level). Odds ratios of carrying *BRCA1-2*mutations were estimated by the logistic regression model and reported with 95% confidence interval (95% CI). All analyses were performed with the statistical package SPSS/7.5 for Windows.

Results
=======

Family screening for BRCA1 and BRCA2 mutations
----------------------------------------------

Genomic DNA from 348 probands of breast-ovarian cancer families was screened for germline mutations in *BRCA1*and *BRCA2*genes. Overall, deleterious germline mutations were detected in 35/348 (10%) familial cases: 23/131 (17.5%) among \"high-risk\" and 12/217 (5.5%) among \"no high-risk\" families (Table [1](#T1){ref-type="table"}). Families with 3 or more BC cases, including the 112 reported in our previous studies, showed a prevalence rate of 11.7% (17/145). Presence of ovarian cancer in family increased the occurrence of *BRCA1-2*germline mutations in either the subset of \"high-risk\" families (5/16; 31%) or the group of \"no high-risk\" families (1/8; 12.5%). No similar variation of mutation rates was observed in families presenting a male member with breast cancer. Stratification of families according to number of breast-ovarian cancer cases showed that *BRCA1/2*positivity was significantly higher in families with 3 or more affected members than those with only two cases, with frequencies of 11.7% and 3.5%, respectively. Among 41/131 \"high-risk\" probands diagnosed at age ≤40 years, 12 (29%) presented a *BRCA1-2*germline mutation.

The overall mutation prevalence was 7% in North Sardinia and 17% and 18% in families from Middle and South Sardinia, respectively. *BRCA*positivity accounts for 11% (8/73), 38% (8/21) and 19% (7/37) in \"high risk\" families from these geographical areas (data not shown).

Spectrum of BRCA1-2 mutations in Sardinia
-----------------------------------------

Overall, 8 distinct *BRCA1*and 5 distinct *BRCA2*pathogenic mutations were found in 35 (10%) out of 348 breast-ovarian cancer families; 11 \"high-risk\" families were positive for *BRCA1*and 12 for *BRCA2*, whereas 1 *BRCA1*and 11 *BRCA2*mutations were identified in \"no high-risk\" families. Therefore, majority (23/35; 66%) of such mutations was found in *BRCA2*, and 12/35 (34%) were in *BRCA1*. All mutations were absent in normal genomic DNA from 103 unrelated healthy individuals (corresponding to 206 control chromosomes) and were classified as disease-causing variants due to their predicted effects on proteins. In Table [2](#T2){ref-type="table"}, all germline mutations detected in our series have been reported. The *BRCA1 c.916_917delTT*mutation was the most represented *BRCA1*variant (three positive families out of 348 cases; 1%), while the variants *c.8764_8765delAG*and *c.3950_3952delTAGinsAT*were the most recurrent mutations in *BRCA2*among patients with a positive family history \[13/348 (4%) and 7/347 (2%), respectively\]. These mutations showed similar frequencies in both the \"high risk\" and no \"high risk\" groups (6.8% vs 5%).

###### 

*BRCA1*and *BRCA2*pathogenetic mutations^a^

  N° of positive families   GENE    EXON   DNA LEVEL                PROTEIN LEVEL          Mutation type   BIC
  ------------------------- ------- ------ ------------------------ ---------------------- --------------- -----
  1                         BRCA1   5      c.300 T\>G               **p.Cys61Gly**         missense        YES
                                                                                                           
  3                         BRCA1   11     c.916_917delTT           **p.Val266SerfsX19**   frameshift      YES
                                                                                                           
  1                         BRCA1   11     c.1099_1100delCA         **p.Thr327fsX1**       frameshift      YES
                                                                                                           
  1                         BRCA1   11     c.1499insA               **p.Phe461fsX18**      frameshift      YES
                                                                                                           
  2                         BRCA1   11     c.1632 A\>T              **p.Lys505X**          non sense       NO
                                                                                                           
  1                         BRCA1   11     c.1638 A \> T            **p.Arg507X**          non sense       NO
                                                                                                           
  2                         BRCA1   11     c.3823_3826delACAA       **p.Asn1235fsX27**     frameshift      NO
                                                                                                           
  1                         BRCA1   14     c.4575delA               **p.Ser1486fsX18**     frameshift      NO
                                                                                                           
  7                         BRCA2   11     c.3950_3952delTAGinsAT   **p.Phe1241fsX17**     frameshift      NO
                                                                                                           
  1                         BRCA2   11     c.6586 C\>G              **p.Ser2120X**         non sense       NO
                                                                                                           
  1                         BRCA2   11     c.6023_6024delTA         **p.His1932X12**       frameshift      YES
                                                                                                           
  13                        BRCA2   20     c.8764_8765delAG         **p.2846X22**          frameshift      YES
                                                                                                           
  1                         BRCA2   18     c.8559+1G\>T             **-**                  splicing        YES

^a^Consensus nomenclature of mutations according to den Dunnen and Antonarakis \[[@B22]\]. Mutations refer to the GenBank accession \#*BRCA1*: no. [U14680](U14680) and *BRCA2*: no. [NM_000059](NM_000059)).

As indicated in Table [2](#T2){ref-type="table"}, [4](#T4){ref-type="table"} out of 8 *BRCA1*mutations and 2 out of 5 *BRCA2*mutations have not been previously reported in either the BIC database. <http://research.nhgri.nih.gov/bic/> or in the Human Gene Mutation Database <http://www.hgmd.cf.ac.uk/ac/>\[[@B23],[@B24]\]. Besides deleterious mutations, complete *BRCA1-2*screening identified 32 missense mutations and 16 intronic variations: 21 already described polymorphisms, 14 variants of unknown clinical significance and 13 novel variants not reported in the BIC database (Table [3](#T3){ref-type="table"}).

###### 

Other genetic variants in *BRCA1*and *BRCA2*

  Gene        Exon     Nucleotide   Codon   Intron   Base change   Mutation type   Nomenclature    BIC citation/Clinical importance
  ----------- -------- ------------ ------- -------- ------------- --------------- --------------- ----------------------------------
  **BRCA1**            561--34              7        T \> C                        IVS7-34 T\>C    YES/no
                       667--57              8        delT                          IVS8-57 delT    YES/no
              11       2196         693              G \> A        missense        D693N           YES/no
              11       2731         871              C \> T        missense        P871L           YES/no
              11       3232         1038             A \> G        missense        E1038G          YES/no
              11       3667         1183             A \> G        missense        K1183R          YES/no
              15       4654         1512             G \> T        missense        S1512I          YES/no
              16       4956         1613             A \> G        missense        S1613G          YES/no
                                            16       A \> G                        IVS16-68 A\>G   YES/no
                                            16       A \> G                        IVS16-92 A\>G   YES/no
              11       1186         356              A \> G        missense        Q356R           YES/unknown
              11       1822         568              C \> T        missense        P568L           YES/unknown
              11       2596         826              C \> A        missense        T826K           YES/unknown
              11       4158         1347             A \> G        missense        R1347G          YES/unknown
              11       4173         1352             G \> A        missense        E1352K          YES/unknown
              16       5075         1652             G \> A        missense        M1652I          YES/unknown
                                            17       C \> T                        IVS17-53 C\>T   YES/unknown
                                            18       G \> A                        IVS18+65 G\>A   YES/unknown
              5        287          56               A \> T        missense        K56N            NO/unknown
              5        288          57               G \> A        missense        G57R            NO/unknown
                                            17       G \> T                        IVS17-53 G\>T   NO/unknown
                                            20       T \> C                        IVS20+34 T\>C   NO/unknown
              22       5469         1784             G \> A        missense        W1784I          NO/unknown
                                                                                                   
  **BRCA2**   5\'UTR   203                           G \> A        missense        203G\>A         YES/no
              10       1379         384              C \> T        missense        S384F           YES/no
              10       1093         289              A \> C        missense        N289H           YES/no
              11       3199         991              A \> G        missense        N991D           YES/no
              11       4469         1414             C \> T        missense        T1414M          YES/no
              11       4486         1420             G \> T        missense        D1420Y          YES/no
                                            16       T \> C                        IVS16-14 T\>C   YES/no
              20       8731         2835             T \> C        missense        S2835P          YES/no
              22                            21       T \> C                        IVS21-66 T\>C   YES/no
              27       10204        3326             A \> T        nonsense        K3326X          YES/no
              1        353          42               C \> T        missense        Y42C            YES/unknown
              10       1409         394              A \> C        missense        E394A           YES/unknown
              11       3623         1132             A \> G        missense        K1132R          YES/unknown
              11       6328         2034             C \> T        missense        R2034C          YES/unknown
              11       6359         2044             G \> C        missense        G2044A          YES/unknown
              25                            24       T \> C                        IVS24-16 T\>C   YES/unknown
              10       1343         372              A \> C        missense        W372N           NO/unknown
                                            2        G \> A                        IVS2+65 G\>A    NO/unknown
                                            4        A \> C                        IVS4+67 A\>C    NO/unknown
                       1042         272              A \> T        missense        N272I           NO/unknown
              11       5967         1910             A \> T        missense        N1910I          NO/unknown
                                            14       C \> T                        IVS14+53 C\>T   NO/unknown
              14       7863         2546             T \> C        missense        S2546P          NO/unknown
              16       7975         2583             G \> A        missense        D2583N          NO/unknown
                                            16       T \> A                        IVS16-32 T\>A   NO/unknown

###### 

Logistic regression analysis to identify predictors of *BRCA*mutations

  Characteristics                 No. of cases   BRCA+ carriers   OR (95% CI)         P
  ------------------------------- -------------- ---------------- ------------------- ----------
  **Age of Onset**                                                                    
  \< 45 years                     139            21 (15%)         1.8 (1.05--4.28)    0.046
  \> 45 years                     209            14 (7%)                              
  **Risk criteria**                                                                   
  high-risk family                131            23 (18%)         3.2 (1.51--6.67)    0.002
  no high risk family             217            12 (6%)                              
  **Ovarian cancer in family**                                                        
  presence                        23             6 (26%)          3.7 (1.44--9.40)    0.006
  absence                         244            27 (11%)                             
  **Bilaterality**                                                                    
  presence                        36             8 (22%)          2.4 (1.05--5.39)    0.038
  absence                         228            25 (11%)                             
  **T**                                                                               
  T1                              151            12 (8%)          2.23 (0.57--8.82)   0.251
  T2                              70             10 (14%)                             
  T3-4                            26             4 (15%)                              
  **N**                                                                               
  N-                              126            15 (12%)         1.02 (0.39--2.67)   0.963
  N+                              112            13 (12%)                             
  **M**                                                                               
  M0                              201            20 (10%)         1.33 (0.15--11.7)   0.797
  M1                              24             3 (12%)                              
  **Tumor Grading**                                                                   
  G1-2                            171            9 (5%)           11.3 (3.38--37.6)   \< 0.001
  G3-4                            33             12 (36%)                             
  **Estrogen Receptor (ER)**                                                          
   ER-                            55             16 (29%)         0.18 (0.06--0.53)   0.002
   ER+                            102            10 (10%)                             
  **Progesteron Receptor (PR)**                                                       
   PR-                            81             21 (26%)         0.22 (0.07--0.66)   0.007
   PR+                            67             6 (9%)                               

The geographical origin of the families positive for deleterious *BRCA1-2*mutations is shown in Figure [1](#F1){ref-type="fig"}. The *BRCA1*variants occurred in families originating from different areas of the island: 7 probands from the South, 2 from the Middle (*BRCA1 c.3823_3826delACAA, BRCA1 c.300 T\>G*) and 1 from the North (*BRCA1 c.1632 A\>T*). Carriers of the *BRCA1 c.916_917delTT*mutation were identified in three unrelated families from the South area. The *BRCA2 c.8764_8765delAG and BRCA2 c.3950_3952delTAGinsAT*variants were found in probands from the North and Middle Sardinia, whereas the remaining *BRCA2*variants were detected in single families from the Central-East coast and South.

![**Geographical distribution of BRCA1-2 mutations carriers in Sardinia**. Symbols indicate villages of origin for the patients presenting deleterious germline mutations in either *BRCA1*or *BRCA2*genes: \"green square\" *BRCA1*c.300 T\>G; green circle *BRCA1*c.916_917delTT; \"green triangle\" *BRCA1*c.1099_1100delCA; \"green arrow\" *BRCA1*c.1499insA; \"green heart\"*BRCA1*c.1632 A\>T; \"green diamond\" *BRCA1*c.1638 A\>T;\"green clubs\" *BRCA1*c.3823_3826delACAA; \"green spades\" *BRCA1*c.4575delA; \"blue square\" *BRCA2*c.3950_3952delTAGinsAT; \"blue triangle\" *BRCA2*c.6586 C\>G; \"blue circle\" *BRCA2 c.6023_6024delTA*; \"blue arrow\" *BRCA2*c.8764_8765delAG; \"blue heart\"*BRCA2*c.8559+1G\>T. Dashed lines delimit the three geographical regions reported in the text.](1471-2407-9-245-1){#F1}

Correlation between BRCA1-2 mutations and probands\' phenotype characteristics
------------------------------------------------------------------------------

As shown in Table [4](#T4){ref-type="table"}, univariate analysis indicated that presence of a *BRCA1-2*mutation correlated significantly with earlier diagnosis age (P = 0.046), classification of the family as \"high risk\" (P = 0.002), recurrence in the family of ovarian cancer (P = 0.006), and development of a bilateral disease (P = 0.038). Considering the pathological parameters of primary tumors, no statistically significant correlation between *BRCA1-2*mutations and primary tumor size (T) or axillary nodal status (N) or distant localization of the disease (M) was observed. However, the *BRCA1-2*mutation rates were significantly higher in the subsets of patients with a more undifferentiated primary carcinoma (tumor grading 3--4, P \< 0.001) and lack of expression of estrogen receptor (ER-, P = 0.002) or progesterone receptor (PR-, P = 0.007).

Discussion
==========

In this study, we have reported the prevalence of *BRCA1-2*germline mutations in patients with a positive family history of breast and/or ovarian cancer from Sardinia, whose population shows genetic peculiarity due to geographical isolation and strong genetic drift \[[@B27],[@B28]\]. Prevalence of *BRCA1-2*mutations may indeed vary among distinct populations due to concurrence of different environmental factors and genetic backgrounds; in other words, patients origin may strongly account for different mutation rates in candidate genes.

In the present study, a germline pathogenic mutation in either *BRCA1*or *BRCA2*was identified in 10% of screened breast-ovarian cancer families (*BRCA1*mutations were detected in about 3% of cases, while *BRCA2*mutations were identified in about 7% of families). *BRCA*positivity reached 17.5% when considering the \"high risk\" families, 29% in families with probands diagnosed at age ≤40 years and 31% in the presence of ovarian cancer in the family. Prevalence rate in \"high risk\" families was higher than that of families with 3 or more affected member regardless of age at onset (11.7%). These results confirm that clinical characteristics such as ovarian cancer in the family, age at diagnosis and number of cases are good predictors for the likelihood to be a *BRCA*mutation carrier.

The overall prevalence of *BRCA1-2*mutations among breast cancer patients from the entire Sardinia was quite similar to that previously reported for breast-ovarian cancer families originating from the Northern part of the island (for both studies, 15% *BRCA*-positive carriers were observed in breast-ovarian cancer families \[[@B14],[@B18]\]. However prevalence of *BRCA*deleterious mutations was higher in Middle Sardinia (38% vs 11% in the North. and 19% in the South). When compared to many other Italian and European studies, the frequency is relatively low \[[@B10]-[@B13],[@B29]-[@B32]\]. Since the sensitivity of mutation detection methods is not complete, some mutations may have remained undetected in the present study. Large genomic deletions, which do escape detection by both DHPLC and direct sequencing may account for a fraction of mutation-negative breast and ovarian cancer families in Sardinia. Overall and even considering a lack of sensitivity of the screening approach used in the present study, the prevalence of *BRCA*mutations in Sardinian families remains low. The selection criterion of two close relatives with breast cancer before the age of 50 years, used in this study, may somehow explain this low prevalence rate, though it is not possible to exclude that a specific genetic background may play a role on breast cancer susceptibility among Sardinian population. Noteworthy, a similar low prevalence of *BRCA*mutations was reported in the Finnish population which has genetic features comparable to the Sardinian one, where the historical, cultural and geographical isolation may have selected specific genetic variants as susceptibility genes for breast cancer \[[@B33]\].

The geographical origin of the families positive for deleterious *BRCA1-2*mutations is shown in Figure [1](#F1){ref-type="fig"}. The *BRCA2 c.8764_8765delAG*and *c.3950_3952delTAGinsAT*variants were previously described as founder mutations in North and Middle Sardinia, respectively. In particular, cases carrying the *BRCA2 c.8764_8765delAG*mutation belonged to unrelated families originating from different villages in the northern part of the island \[[@B11],[@B14]\]; most of families genotyped with markers flanking the *BRCA2*gene at 13q12-q13 locus were demonstrated to share a large haplotype, not found in control chromosomes from the same geographical area \[[@B11]\]. Conversely, the *BRCA2 c.3950_3952delTAGinsAT*, which was previously reported as a founder mutation, was instead running in families belonging to a single extended pedigree confined to a small village of the central part of Sardinia \[[@B19]\]. The *BRCA1*variants occurred in families originating from different areas of the island without a defined geographical clustering, though about half of the cases carrying the *BRCA1*mutations originated from the South Sardinia. Interestingly, in three unrelated families from the South and Middle Sardinia we identified carriers of the *BRCA1 c.916_917delTT*mutation that has been reported in breast-ovarian cancer families from South Italy \[[@B34]\]. Altogether, the geographical distribution of the genetic variants in the island, suggests that *BRCA1-2*mutations are related to the specific three large areas of Sardinia, which reflects its ancient history: a) the North area, delimited by the mountain chain crossing Sardinia and linguistically different from the rest of the island (where the *c.8764_8765delAG*variant acts as founder mutation); *b*) the Middle area, land of the ancient Sardinian population and domain of pastoral culture (where *BRCA2*mutations are still more common than *BRCA1*mutations); and *c*) the South-West area, with many Phoenician and Carthaginian archeological sites (where *BRCA1*mutations are prevalent).

Majority of *BRCA1-2*germline mutations identified in Sardinian families is unique: most of the variants were detected in single families and 6 were novel mutations.

The frequencies of *BRCA1*or *BRCA2*mutations among breast-ovarian cancer families varies widely between populations world-wide: Icelandic breast cancer families present almost exclusively *BRCA2*mutations \[[@B30]\], roughly equal numbers of *BRCA1*and *BRCA2*mutations have been described in French Canadian or British breast cancer families \[[@B35],[@B36]\], while a clear prevalence of *BRCA1*mutations has been observed in the United States \[[@B37],[@B38]\]. In this study *BRCA2*mutations were more frequent than *BRCA1*mutations, although it should be taken into account that a high proportion of families are carrying the *BRCA2 c.8764_8765delAG*founder mutation. Mutations in *BRCA2*gene have been detected in up to 40% of male breast cancers in Iceland \[[@B39]\]; in our isolated population, we detected a *BRCA2*mutation in 1/14 (7%) men with breast cancer with a frequency similar to that reported for male breast cancers in USA (4%) \[[@B40]\]. Again, these findings suggest that other environmental and/or genetic factors are contributing to the susceptibility to male breast cancer in Sardinia.

Specific pathological features have been reported in hereditary breast cancer with differences between *BRCA1*and *BRCA2*associated tumors \[[@B41]\]. In our series, the analysis of clinico-pathological characteristics showed some differences between *BRCA1-2*wild type and mutation carriers. Though no correlation with the stage of disease (the main prognostic factor for breast cancer patients) was observed, the presence of *BRCA1-2*mutations were significantly associated with some pathological characteristics (higher tumor grading, lack of expression of estrogen/progesterone receptors) which are recognized to have a negative impact on prognosis. Unfortunately, data from mutation screening of *BRCA1*and *BRCA2*were combined for the statistical analysis due to the low number of positive cases for each single gene in our series, although distinct differences in both molecular pathology and histopathology have been shown according to the specific carrier status.

Conclusion
==========

In summary, our results on the entire Sardinian population demonstrated that: *a*) prevalence of *BRCA1*and *BRCA2*mutations is 10% in familial breast-ovarian cancer; *b*) the spectrum of mutations among Sardinians is unique; *c*) some specific phenotypic features may be predictive for the presence of *BRCA1-2*germline mutations and should be therefore considered when counselling Sardinian patients about undergoing genetic testing. On this regard, the fulfilment of one or more of the following criteria seems to increase the probability to detect a predisposing *BRCA1-2*mutation among Sardinian breast cancer patients: *a*) high-risk classification of the patient\'s family; *b*) presence of at least one family member with ovarian cancer; *c*) occurrence of synchronous or asynchronous bilateral breast carcinoma.

Our findings further confirm that mutation frequency for *BRCA1*and *BRCA2*as cancer susceptibility genes for breast-ovarian carcinoma needs to be evaluated in each distinct geographical area. Finally, the absence of any *BRCA1*or *BRCA2*mutation in majority of \"high-risk\" families with breast-ovarian cancer support the general hypothesis that additional breast cancer susceptibility genes remain to be identified.
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